MNTA Shares Outstanding History
Below is a table of the MNTA shares outstanding history going back to 2/26/2010:

Date MNTA Shares Outstanding
2/26/201044.84M
5/3/201044.92M
7/28/201045.28M
11/1/201045.46M
2/28/201149.94M
5/2/201150.85M
8/1/201151.17M
10/31/201151.24M
2/15/201251.33M
5/2/201251.52M
8/3/201251.68M
11/2/201251.69M
2/15/201351.75M
5/6/201351.93M
8/1/201352.28M
11/4/201352.30M
2/15/201452.48M
4/30/201452.74M
7/31/201452.81M
10/31/201453.05M
2/13/201554.97M
4/27/201559.36M
7/31/201568.81M
10/30/201569.00M
2/1/201669.14M
4/12/201669.50M
7/29/201670.74M
8/31/201670.98M
10/31/201671.02M
12/12/201671.23M
1/27/201771.31M
2/1/201771.85M
4/24/201774.20M
7/26/201776.23M
10/30/201776.39M
2/9/201876.86M
5/2/201877.59M
8/3/201878.31M
11/1/201878.56M
2/11/201998.51M
4/29/201998.61M
7/31/201998.71M
10/22/201998.92M
2/13/2020117.28M
4/23/2020117.71M
8/3/2020118.85M

Also see: MNTA Market Cap History
MNTA YTD Return
MNTA Historical Shares Outstanding:
+9.79% CAGR
MNTA Historical Shares Outstanding: +9.79% CAGR

Mouse over chart for data details
2/26/2010 ...8/3/2020
Momenta Pharmaceuticals is a biotechnology company focused on the discovery and development of biologic therapies for the treatment of rare immune-mediated diseases. Co.'s programs include: M281, a fully-human anti-neonatal Fc receptor, aglycosylated immunoglobulin G (IgG1), monoclonal antibody; M254, a hyper-sialylated immunoglobulin; M230, a novel recombinant trivalent human IgG1 Fc multimer; and M710, a biosimilar of EYLEA, a vascular endothelial growth factor inhibitor indicated for the treatment of Neovascular (Wet) Age-related Macular Degeneration, Macular Edema following Retinal Vein Occlusion, Diabetic Macular Edema (DME), and Diabetic Retinopathy in patients with DME. We show 46 historical shares outstanding datapoints in our coverage of MNTA's shares outstanding history.

Understanding the changing numbers of MNTA shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like MNTA versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching MNTA by allowing them to research MNTA shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree MNTA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Momenta Pharmaceuticals (MNTA) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

MODD Shares Outstanding History
MODV Shares Outstanding History
MOH Shares Outstanding History
MORF Shares Outstanding History
MOTS Shares Outstanding History
MOVE Shares Outstanding History
MRIC Shares Outstanding History
MRK Shares Outstanding History
MRKR Shares Outstanding History
MRNA Shares Outstanding History
More Healthcare companies »

 

MNTA Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2022, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.